Analytical Data
-
Gene name
Integrin alpha V beta 3
- Application
-
Alternative Names
CD51; ITG-AV; MSK8; VNRA; Vitronectin Receptor,Alpha Polypeptide
-
Species
Rat
-
Source
E. coli
-
Tag
N-His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
A0A0G2JVZ6
-
Expression Region
Pro469~Leu918
-
Molecular Weight
46&27kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
Integrin alpha V beta 3 is a crucial integrin heterodimer that plays a significant role in cell adhesion, migration, and signal transduction processes. This integrin is primarily expressed on activated endothelial cells and various types of cancer cells, making it an important target for cancer therapy and drug delivery systems. Research has demonstrated that alpha V beta 3 is involved in tumor angiogenesis and metastasis, as it mediates the interaction between cells and the extracellular matrix (ECM). The overexpression of this integrin in many tumors highlights its potential as a biomarker for cancer diagnosis and prognosis. Consequently, the development of recombinant alpha V beta 3 proteins has garnered attention in the scientific community, as these proteins can be used to further understand the integrin's biological functions, its role in pathological conditions, and to facilitate drug design. Recombinant integrins can serve as effective tools for evaluating prospective therapeutic agents that target integrin-mediated pathways, providing insights into the mechanisms of tumor progression and enabling the design of integrin-based therapies. Moreover, studying these proteins can help elucidate the molecular interactions that occur during cell adhesion and migration, contributing to advancements in tissue engineering and regenerative medicine. Overall, the research surrounding recombinant integrin alpha V beta 3 underscores its significance in both basic biology and clinical applications, offering numerous avenues for exploration in cancer research and therapeutic development.
